Conclusion: J Clin Sleep Med. 2021;17(9):1881-1893.
PubMed 34743789 ↗Armodafinil
Also known as Nuvigil, Waklert
The short answer. More people than not who report on Armodafinil say it helped (65% of 113). It is most often used for focus: 87% of 76 reports say that improved. It is well studied — 34 meta-analyses on PubMed. The most common complaint is anxiety.
From 222 mentions in total — the rest didn't say how it went and aren't counted.
What Armodafinil does, according to users
Of the people who reported each effect, the share who said it got better.
3 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 34 meta-analyses on PubMed ↗ · 44 randomized trials ↗
Conclusion: Ar/mod reduces negative symptoms with a small effect size; the absolute advantage is also small, and the advantage disappears when chronically ill patients or those with high negative symptom burden are treated. Ar/mod does not benefit or worsen other symptom dimensions in schizophrenia.
PubMed 25306261 ↗Conclusion: We believe our analysis is a fairer analysis of the risk-benefit profile of this indication. Clinicians may want to use this data to balance the risks and benefits on a case-by-case basis with their patients.
PubMed 26846828 ↗Conclusion: J Clin Sleep Med. 2021;17(9):1895-1945.
PubMed 34743790 ↗62 human trials on ClinicalTrials.gov test Armodafinil — 48 completed, 1 recruiting now. See all on ClinicalTrials.gov ↗
- Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder · Schizophrenia, Schizoaffective Disorder · 2010
- Sleep/Wake State Assessment with Non-invasive Earbuds · Hypersomnolence · 2023
- Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma · Fatigue · 2019
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
The current US prescription label has no boxed warning.
20,967 adverse-event reports mention Armodafinil. Most often reported:
- Drug ineffective · 1,574
- Fatigue · 1,508
- Nausea · 1,473
- Headache · 1,402
- Anxiety · 1,178
- Somnolence · 1,101
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
NIH has funded 2 research projects with Armodafinil in the title, $747,358 in total (2010–2012). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Armodafinil ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I experience significantly less anxiety with armodafinil than modafinil, and some others do as well.”
“Felt "wakefulness" in the simplest sense of the word. That's actually the best I can describe it, so it does **exactly** what it purports to do.”
“I experienced huge focus and drive—I rattled through my work tasks back-to-back. Great mental clarity and recall.”
“Armodafinil (Waklert) at 75mg gives me 2-3 hours of a boost similar to a primed caffeine feeling, without jitters, followed by 10-12 hours of being in a completely awakened state.”
Armodafinil compared
Other options for focus
Sources
- User reports: 222 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate